Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700026815

Trial Profile

Clinical Trials Insight: 700026815

Phase of Trial: Phase I

Latest Information Update: 08 Dec 2010

At a glance

  • Drugs Danoprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors InterMune
  • Most Recent Events

    • 01 Oct 2008 Status changed from active, no longer recruiting to completed.
    • 24 Sep 2008 Results from this study will be presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Oct. 31 - Nov. 4, in San Francisco, California.
    • 29 May 2008 It is expected that results from all dose cohorts will be submitted for possible presentation at this years Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) held in Oct-Nov, reported in an InterMune media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top